-
Cyclodextrin Nano-Adsorbents for Uremic Toxins
2026-09-29
The reference study evaluates magnetic nanoparticles coated with α-, β-, or γ-cyclodextrin as recoverable adsorbents for uremic toxins, combining surface characterization with quantitative mass spectrometry. Its central finding is that adsorption was not governed simply by metabolite concentration, emphasizing the importance of cyclodextrin cavity size, surface chemistry, incubation conditions, and solution composition in blood-cleansing technologies.
-
Berberine and Evodiamine in GERD: TAS2R38/TRPV1
2026-09-28
A 2024 study reports that berberine and evodiamine reduce esophageal injury and inflammatory responses in rat and cell models of gastroesophageal reflux disease. Receptor-silencing and pharmacological experiments support a role for TAS2R38 and TRPV1 signaling, linking these receptors to MAPK/NF-κB activity, epithelial barrier proteins, and macrophage polarization.
-
Alda 1 Workflows for Cardiac ALDH2 Research
2026-09-27
Alda 1 supports ALDH2-focused experiments spanning aldehyde detoxification, cardiomyocyte proliferation, and preclinical injury models. This guide connects a recent pressure-overload study to practical assay design, while separating literature findings from suggested pilot conditions.
-
Alda 1: ALDH2 Activator for Research
2026-09-26
Alda 1 is an ALDH2 activator used to study aldehyde detoxification and cardiac injury. Product information reports activity enhancement for both ALDH2*1 and ALDH2*2, while mouse research links ALDH2 activation with cardiomyocyte proliferation and delayed pressure overload-induced heart failure.
-
Alda 1 and Cardiac Remodeling Beyond Ischemia
2026-09-26
Alda 1 is an ALDH2 activator that helps researchers examine how aldehyde handling intersects with cardiomyocyte proliferation and pressure-overload remodeling. This article explains the 2025 mouse findings and how to design assays that distinguish cellular regeneration from reduced injury.
-
Sitagliptin Phosphate Monohydrate in Cell Assays
2026-09-25
This practical guide explains how to use Sitagliptin phosphate monohydrate (SKU A4036) to investigate DPP-4 biology without confusing enzyme inhibition with cell viability. It covers assay controls, formulation, interpretation, and transparent criteria for selecting a research-grade compound.
-
HNF4A-AS1 Loss and Sorafenib Resistance in HCC
2026-09-25
A 2024 study links reduced liver-specific lncRNA HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through METTL3- and YTHDF3-dependent regulation of DECR1 mRNA. Its findings connect lipid remodeling and polyunsaturated fatty acid availability to ferroptosis, while highlighting questions for future validation in patient-derived models.
-
Fosinopril Pharmacokinetics and Clinical Potential
2026-09-24
Shionoiri and colleagues’ 1997 review brings together clinical evidence on fosinopril’s conversion to fosinoprilat, its dual renal and biliary elimination, and its effects on blood pressure and cardiovascular hemodynamics. Its central translational insight is that disposition through both urine and bile may make fosinoprilat less dependent on renal clearance than many other ACE inhibitors, while the review also highlights evidence gaps in drug interactions and clinical subgroups.
-
Resiniferatoxin (RTX) Workflows for TRPV1 Pain Research
2026-09-24
Use Resiniferatoxin to separate the initial TRPV1 calcium response from the longer-lasting desensitization of sensory neurons in pain models. A recent cyclodextrin study adds a practical comparison: membrane cholesterol depletion reduced RTX-associated mechanical hyperalgesia, but not thermal hyperalgesia, pointing to value in measuring distinct sensory endpoints.
-
Angiotensin II: From GPCR Signal to Assay Design
2026-09-23
Angiotensin II is a powerful experimental probe for receptor signaling, vascular remodeling, and hypertension mechanism study. This guide connects peptide pharmacology with assay design and explains why recent ACE2 research changes how RAS experiments should be interpreted.
-
Iptacopan (LNP023) Complement Research Workflows
2026-09-22
Iptacopan (LNP023) gives researchers a selective, reversible way to interrogate alternative complement pathway amplification across biochemical, serum, cellular, and animal systems. This workflow-focused guide connects assay design, pathway controls, hemolysis readouts, translational modeling, and bleeding-risk interpretation without treating clinical risk scores as substitutes for mechanistic validation.
-
Fosinopril Sodium: Translational ACE Inhibition
2026-09-22
A mechanism-led guide to using Fosinopril sodium in hypertension research, cardiovascular disease models, and renal hemodynamics studies, with emphasis on target engagement, prodrug activation, exposure control, and translational endpoint design.
-
Coumestrol Drives PMAIP1-Linked Ferroptosis in RA
2026-09-21
A 2026 study identifies a TRIM3–PMAIP1 protein-stability axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. The findings connect mitochondrial stress, iron accumulation, inflammatory cytokine production, and synoviocyte proliferation, while also highlighting the need to distinguish this mechanism from Coumestrol’s established nuclear receptor activity.
-
Resiniferatoxin: From TRPV1 Biology to Translation
2026-09-21
Resiniferatoxin (RTX) is more than an ultra-potent TRPV1 agonist: it is a mechanistic tool for testing how selective sensory-neuron activation becomes durable functional silencing. This article connects RTX biology with GERD pathway research, pain-model design, route selection, and translational decision-making.
-
Machine Learning for Senolytic Discovery
2026-09-20
The reference study shows that cost-effective machine-learning models trained on published, heterogeneous data can identify candidate senolytics without requiring a large new screening campaign. Experimental validation of ginkgetin, periplocin, and oleandrin illustrates how computational prioritization can reduce discovery costs while exposing important questions about selectivity, potency, and transferability across senescent cell models.